Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that results from a study designed to perform a systematic review of the literature and establish the level of evidence for the Company’s DecisionDx®-Melanoma gene expression profile test were published in the December 2019 issue of the American Journal of Clinical Dermatology. The results show that the DecisionDx-Melanoma test achieves a higher level of evidence than determined by major organizations that publish guidelines on melanoma management. DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors. In this independent study by Dubin, et al. titled, “Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma,” the researchers conducted a review of seven development and validation studies for the DecisionDx-Melanoma test. They then applied attributes of each study to the level of evidence criteria for the American Joint Committee on Cancer (AJCC), National Comprehensive Cancer Network (NCCN) and American Academy of Dermatology (AAD). The AJCC, NCCN and AAD are considered major authoritative organizations that many dermatologists rely upon to provide skin cancer guidelines, and each employs a unique ranking system to assign a level of evidence to the management of melanoma.